On November 2, 2022, Rubius Therapeutics announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and will engage an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of the Company or a merger.